PI Industries Limited Q2 Profit Falls 70% as Revenue Slips

PI Industries Limited reported a 70% year-on-year fall in Q2 FY27 net income to ₹1.22 billion, while revenue declined 5.8% to ₹17.6 billion. The result followed a sharp share-price correction and has brought attention to earnings recovery, valuation and the performance of its agrochemicals and pharma businesses.

What did PI Industries report in Q2 FY27?

PI Industries reported weaker year-on-year earnings in Q2 FY27, with earnings per share falling to ₹8.05 from ₹26.98 in Q2 FY26. Revenue was ₹17.6 billion, down 5.8% from the corresponding quarter, while net income fell to ₹1.22 billion from the prior-year period, a decline of 70%.

The company disclosed unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, following a board meeting on November 4, 2026. The quarterly numbers extend a period of weaker reported financial performance. In Q3 FY26, PI Industries had reported revenue of ₹14.4 billion, down 24% year on year, and net income of ₹3.11 billion, down 17%.

The annual figures in the supplied data also show a softer base going into FY27. PI Industries recorded FY26 revenue of ₹67.14 billion, compared with ₹79.78 billion in the preceding year, while earnings declined 20.44% to ₹13.21 billion.

Why has PI Industries stock been under pressure?

PI Industries stock has been under pressure as investors assessed falling earnings and reduced profitability. The supplied performance overview shows a 51.26% one-year decline for the stock, compared with a 3.03% fall in the S&P BSE SENSEX over the same period. Other social-media discussions put the one-year drop at about 54%.

The recent decline was particularly sharp, with posts citing a 19% to 20% fall over a week and share prices around ₹1,758 to ₹1,761. Separately, reports said the stock reached a 52-week low of ₹1,708 as the sell-off deepened. These price moves followed concerns around the company’s operating performance, including a reported 39.43% year-on-year fall in Q4 FY26 net profit to ₹200.20 crore.

The context does contain one encouraging operating datapoint from Q1 FY27. PI Industries reported 12% domestic volume growth and 50% growth in biologicals, alongside revenue of ₹17,023 million, a 57% gross margin and a 22% EBITDA margin. Those indicators have yet to offset the concern created by the subsequent weak quarterly profit figures.

Is PI Industries valuation attractive after the fall?

PI Industries traded at a forward price-to-earnings ratio of 29 times after the recent fall, above the stated Indian chemicals-industry average of 21 times. That comparison indicates that the stock's valuation still requires investors to weigh expected earnings recovery against the scale of the recent earnings decline.

The earnings outlook cited in the discussion remains an important part of that calculation. PI Industries is forecast to post earnings per share of ₹44.54 next year, compared with ₹87.06 last year. A lower expected earnings base can keep the forward multiple elevated even after a significant decline in the share price.

Analyst views remain mixed rather than uniformly positive. The average rating from 25 analysts is Hold, and their cited 12-month average target price is ₹2,274, representing a 30.65% increase from the latest referenced price. Price targets are estimates, not assurance of future returns, particularly when quarterly profitability is under pressure.

What could investors watch next at PI Industries?

Investors could watch whether PI Industries can stabilise revenue and improve profit conversion in coming quarters. The key reported issue is the difference between a relatively modest 5.8% revenue decline in Q2 FY27 and a much steeper 70% fall in net income, which makes margins and operating execution central to the next set of results.

The product pipeline is another area to track. PI Industries informed exchanges about the unveiling of Pioxaniliprole, described as India’s first indigenously discovered insecticide molecule. The company operates through Agro Chemicals and Pharma, selling insecticides, fungicides, herbicides, biologicals, crop solutions, plant nutrients, specialty chemicals, custom synthesis and manufacturing services, and pharmaceutical products across India and international markets.

The company has also notified an interaction with ICICI Prudential Asset Management Company Limited. Investors may look for management commentary from such engagements on demand, biologicals growth, the pharma segment and the earnings outlook. The supplied data does not provide forecasts for these individual business lines.

Conclusion

PI Industries faces a difficult earnings comparison after Q2 FY27 revenue fell 5.8% and net income declined 70% year on year. The share-price fall has reduced the stock sharply over one year, but the stated 29-times forward P/E remains above the cited chemicals-industry average, reflecting uncertainty over the pace of recovery.

The next results and management communication will be important for assessing whether domestic volume growth and biologicals growth can support a turnaround. Investors will also watch progress around Pioxaniliprole, the forecast EPS of ₹44.54 for next year and any further changes in analyst expectations or target prices.